PHA Case Studies V (Answers)
|
|
- Anissa Mosley
- 6 years ago
- Views:
Transcription
1 PHA 5128 Case Studies V (Answers) 1. A 100 kg patient is to be treated p.o. with sodium phenytoin capsules. Assuming a phenytoin volume of distribution of 0.7 L/kg, Km of 4 mg/l and Vmax of 7 mg/kg/day, calculate the following: For a 100 kg patient, Vd 0.7 L/kg 100kg 70 L Km 4 mg/l (a) 7mg / day Vmax 100kg 700mg / day k The loading dose to produce an initial concentration of 18 mg/l. How would you administer this dose? For a loading dose to produce a Cp of 18 mg/l, Vd Cp LD (70L)(18mg / L) (0.92)(1) ~ 1370mg Given as IV infusion of 50 mg/min or 3 oral doses of 500, 400, 400 mg every 2hrs. (b) The daily maintenance dose to produce an average steady state concentration of 15 mg/l. The concentration at steady-state is given by D Cpss Cl τ Since phenytoin exhibits nonlinear clearance, Vm Cl Km+ C pss Inserting this expression for Cl into the equation above and solving for dose D gives F:\INTRDEPT\Derendorf\cs5-ans-02.doc 1
2 Vm C pss τ D ( Km + C pss) S F For Cpss of 15 mg/l, the daily dose is (700mg / day)(15mg / L)(1day) D (4mg / L + 15mg / L)(0.92)(1) 600mg/day 2. A patient (35 years old, 65 kg) is to be started on intravenous phenobarbital sodium. The therapeutic range is mg/l. A loading dose is given so as to yield a Cp 0 of 30 mg/l. Calculate this loading dose and the daily maintenance dose to produce an average steady state concentration of 20 mg/l. Based on average PK parameters for a 65 kg patient, Vd (0.7L/kg)(65kg) 45.5L Cl (4 ml/hr/kg)(65 kg) 260 ml/hr 6.24 L/day The loading dose is Vd Cp LD L)(30mg / L) (0.9)(1) 1517mg ~ 1500mg To maintain an average plasma concentration of 20 mg/l, Cl Cpss τ MD ( 6.24L / day)(20mg / L)(1day) (0.9)(1) ~ 140 mg/day F:\INTRDEPT\Derendorf\cs5-ans-02.doc 2
3 3. Estimate a digoxin loading dose that will produce a plasma concentration of 1.5 µg/l for a 70 kg patient R.J., being treated for mild to moderate congestive cardiac failure. How should this loading dose be divided and what would be an appropriate interval between doses? Assume R.J. is a 50- year-old male with a serum creatinine of 1.0 mg/dl. Calculate a maintenance dose that will achieve an average plasma digoxin concentration of 1.5 µg/l. If the patient had had a serum creatinine of 5 mg/dl, would the estimated loading dose have been different? Assuming population average parameters, the Vd for a 70 kg patient is Vd (7.3 L/kg)(70 kg) 511 L (i) Assuming loading dose is administered orally as tablets (S 0.7), Vd Cp LD 0 (511L)(1.5µ g / L) 1095µ g ~ 1000µ g (0.7)(1) (ii) For a 70 kg male patient, 50 y.o. patient with CHF (moderate) and SCr of 1.0 mg/dl, Cl(ml/min) (0.33 ml/min/kg)(weight in kg) + (0.9) Cl creat (in ml/min) In order to use this equation, Cl creat must be determined. Cl creat (140 age)( weight) ( male) 72 Scr (140 50)(70) 87.5ml/ min (72)(1) The digoxin clearance is then Cl (0.33 ml/min/kg)(70) + (0.9)(87.5 ml/min) 1L 60min 24hr 101.9ml/ min 1000ml 1hr 1day L/day The daily dose of digoxin is then found to be F:\INTRDEPT\Derendorf\cs5-ans-02.doc 3
4 Cl C pss τ Dose ( 146.7L / day)(1.5µ g / L)(1day) (0.7)(1) 314.4µg (iii) If Scr is 5 mg/dl rather than 1.0 mg/dl, a different loading dose would be calculated. Although Vd and Cl are independent kinetic parameters, certain disease states may affect them both. An empirical expression for the Vd of digoxin has been derived in terms of Cl creat : Vd(L) (3.8 L/kg)(weight in kg) + (3.1) Cl creat (ml/min) An increased Scr indicates renal dysfunction and a smaller Cl creat. Thus, based on this equation, Vd is decreased and a smaller loading dose is needed, Vd Cp LD 0 F:\INTRDEPT\Derendorf\cs5-ans-02.doc 4
5 4. GH is a 56 year old liver transplant patient. In the hospital, he received 300 mg QD cyclosporin as an iv infusion which resulted in a trough level of 200 ng/ml. After he is discharged, he will continue with oral cyclosporine treatment. Make a dose recommendation for GH. If 300 mg cyclosporine provides correct plasma levels, dose simply needs to be converted to oral dose (F 0.3) New dose F F current NewFormulation x Current dose 1 (300mg ) 1000mg / day 0.3 Give 500 mg every 12 hours. F:\INTRDEPT\Derendorf\cs5-ans-02.doc 5
6 5. Camille Carton is a 36 year old female with newly diagnosed atrial fibrillation with accompanying severe obesity. She is 5'7" tall and weights 338 Ibs. Her cardiologist calls the pharmacy and states that he has had trouble in dosing similar patients in the past and would like some assistance in designing a loading and maintenance IV Lanoxin dosage regimen. She has no other complicating drugs or diseases (serum creatinine 0.7 mg%) except that she is being continued on Quinidex Extentabs 300 mg Q8H which she has been reliably taking for 3 years. Respond to the physician's request and in addition, volunteer some helpful TDM guidelines. Upon receiving your recommended digoxin regimen for 5 days, you have the following serum digoxin concentrations: Start date 2/2/92 at 8 a.m., SDC 1.3 ng/ml at 7 a.m. 2/4/92 and 1.7 ng/ml at 7 a.m., 2//7/92. Prepare a follow-up consult and include a warning as to what might be expected if quinidine were discontinued but digoxin remained at the current dosage. Given information: 5'7", 36 y.o. female 338 lbs Scr 0.7 For any calculations, IBW should be used. IBW x (height above 5') 45 + (2.3)(7) 61.1 kg Creatinine clearance may now be calculated: Cl creat (0.852)(140 age) weight (female ) (72) Scr ( 0.85)(140 36)(61.1) (72)(0.7) 107 ml/min Cl and Vd may be estimated using the empirical equations in the text (p. 201) Cl TOT (0.8 ml/min/kg)(ibw) + Cl creat (ml/min) (0.8 ml/min/kg)(61.1 kg) ml/min 156 ml/min Since quinidine is being co-administered, this value is multiplied by 0.5. Thus, for this patient F:\INTRDEPT\Derendorf\cs5-ans-02.doc 6
7 Cl TOT (156 ml/min)(0.5) 78 ml/min 1440 min/day 1L/1000 ml 112 L/day Vd 3.8L / kg IBW Cl ( ml creat ( 3.8L / kg)(61.1kg) + (3.1)(107) / min) 564 L (564 L)(0.7) 395 L if on quinidine as well To obtain an initial concentration of 1.5 µg/ml Cp 0 D Vd is solved for D (or LD/loading dose) to give LD Cp 0 Vd (1.5 µg/l)(395 L) 593 ~ 600 µg A maintenance dose to provide the same concentration is MD Cl C pss τ (112 L/day)(1.5 µg/l)(1 day) 168 µg/day ~ 175 µg/day Since two points are given, a better estimate of the clearance for this patient may be obtained using Cl ( Dose / τ) ( Cp Cp average 2 Cp1) Vd t (See page ; see also equation 58 p. 87) F:\INTRDEPT\Derendorf\cs5-ans-02.doc 7
8 (175µ g / day) Cl 1.5µ g / L 66.5 L/day [( ) µ g / L(564L) /3days] If the patient were to be continued on the current dosing regimen of 175 µg/day, the average would be Cpss D C pss Cl τ 175µ g / day (66.5L / day)(1day) 2.6µ g / L This is above the therapeutic range (although concentrations above 2 µg/l are used for atrial fibrillation according to the book). To provide an average concentration of 1.5 µg/ml, MD Cl C pss τ (66.5 L/day)(1.5 µg/day)(1 day) ~ 100 µg/day This dose is small since clearance had been overestimated for this patient. If quinidine were discontinued, clearance would increase (double) and maintenance dose would need to be increased to provide therapeutic concentrations. F:\INTRDEPT\Derendorf\cs5-ans-02.doc 8
PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007
PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007 1. L.J., a 30 year old male, was diagnosed congestive heart failure (CHF). He is 5'9" tall and weights 80 kg. He was given Furosemide
More informationName: UFID: PHA Exam 2. Spring 2013
PHA 5128 Exam 2 Spring 2013 1 Carbamazepine (5 points) 2 Theophylline (10 points) 3 Gentamicin (10 points) 4 Drug-drug interaction (5 points) 5 Lidocaine (5 points) 6 Cyclosporine (5 points) 7 Phenobarbital
More informationTDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.
TDM Lecture 7 5 th Stage TDM of Digoxin Digoxin uses and elimination Uses: Digoxin is usually used in heart failure associated and atrial fibrillation. Elimination: About 75% of digoxin clearance occurred
More informationCarbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8
PHA 5128 Dose Optimization II, Spring 2013, Case Study IV Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationPHA 5128 Spring 2009 First Exam (Version B)
Name: UFID: PHA 5128 Spring 2009 First Exam (Version B) On my honor, I have neither given nor received unauthorized aid in doing this assignment. Print: Sign: Version B Q1: Phenytoin (10) Q2: procainamide
More informationTDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages
TDM Lecture 8 5 th Stage TDM of Digoxin Use of Digoxin Serum Concentrations to Alter Dosages Linear Pharmacokinetics Method This method is used in steady-state condition. We compute the new dose of digoxin
More informationPHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5128 Final Exam Spring 2004 Version A On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name There are 18 questions. Total /120 pts Final 2004 1 1. T.P., a 66-year-old,
More informationPHA 5128 Spring 2000 Final Exam
PHA 128 Spring 2000 Final Exam On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name TYPED KEY Questions Points 1. /1 2. /1 3. /1 4. /1. /10 6. /10. /10 8. /10
More informationThus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.
PHA 5128 Dose Optimization II, Spring 2012, Case Study V Solution If you have any questions regarding this case study, do not hesitate to contact Benjamin Weber (benjaminweber@ufl.edu). Please remember
More informationCase Study 2 Answers Spring 2006
Case Study 2 Answers Spring 2006 1. The volume of distribution of diazepam in a group of normal subjects (60 kg, ideal body weight) was found to be 105 L. In another group of patients (110 kg), the volume
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationLD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)
PHARMKIN WORKSHOP A PHARMACOKINETICS TEACHING SIMULATION Joseph K. Ritter, Ph.D. Associate Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@mail2.vcu.edu Tompkins-McCaw Libray Room 2-006
More information. Although there is a little
PHA 58 Spring 007 Case study 4. Baby girl A, 3kg, 5 days, is receiving phenobarbital because of neonatal seizures. An IV loading dose of phenobarbital sodium of 0mg/kg was given followed by maintenance
More informationPHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.
PHA 58 ase Study 4 (Answers) Spring 4. PT is a patient stabilized on chronic phenytoin therapy. She has just been diagnosed with rheumatoid arthritis and her physician would like to start her on high dose
More informationAdjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes
Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes Brian Hardy, PharmD, FCSHP, FCCP Coordinator Education and Clinical Programs Department of Pharmacy Sunnybrook
More informationPHARMACOKINETICS SMALL GROUP II:
PHARMACOKINETICS SMALL GROUP II: Question 1 Why are some drug therapies initiated with a loading dose? Emphasize that LD establishes initial therapeutic level quickly. The time to reach the steady-state
More informationCLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE
CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE Joseph K. Ritter, Ph.D. Assoc. Professor, Pharmacology and Toxicology MSB 536, 828-1022, jritter@vcu.edu This self study module will reinforce the
More informationpharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.
Therapeutic drug monitoring (TDM) Is a tool that can guide the clinician to provide effective and safe drug therapy in the individual patient. Monitoring can be used to confirm a plasma drug concentration
More informationPHA5128 Dose Optimization II Case Study 3 Spring 2013
Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What
More informationBasic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy
Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy I. General principles Applied pharmacokinetics - the process of using drug concentrations, pharmaco-kinetic
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationA Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients
CMU. J. Nat. Sci. (2012) Vol. 11(1) 77 A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients Yupaporn Preechagoon 1 and Peeraya Somsaard 2* 1 Department
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More information4WS Neurology. Table of Contents
4WS Neurology Table of Contents 1. Phenytoin Preparations... Page 2 Monitoring... Page 2 Therapeutic Range... Page 2 Loading Doses... Page 2 Maintenance Doses... Page 3 Sampling Times... Page 3 Dose Adjustment...
More informationPolicy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
More informationPHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4120 Second Exam Key Fall 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /10 ponts 2. /20 points 3. /10 points 4. /10 points
More informationMyrna Y. Munar, Pharm.D., BCPS
Phenytoin PK Myrna Y. Munar, Pharm.D., BCPS Associate Professor Clickers Turn clicker on by pressing down menu button Enter you OSU student ID number The up/down diagonal arrows button on the left is the
More informationPHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2013 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points Set I 20 pts Set II 20 pts Set III 20 pts Set IV 20 pts Set
More informationClinical Pharmacokinetics. Therapeutic Drug Monitoring of Phenytoin
Clinical Pharmacokinetics Therapeutic Drug Monitoring of Phenytoin Dr. Maysa Suyagh School of Pharmacy University of Jordan Phenytoin primarily used as an anticonvulsant and has been used in the treatment
More informationPHA Final Exam Fall 2006
PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationDoses Target Concentration Intervention
1 Doses Target Concentration Intervention 2 Problem 1 Questions 1-2 Susan is a 28 year old woman who has had epilepsy since she was 5 years old. She has been on, and off, anticonvulsant medication since
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationPHARMACOKINETICS SMALL GROUP I:
PHARMACOKINETICS SMALL GROUP I: Question 1 Absorption of the anti-fungal agent, itraconazole, is dependent on a low gastric ph. Calculate the relative concentrations of a weak acid (with a pka of 5.4)
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationINTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS
Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title
More informationLearning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD
Learning Outcomes CPPD #7 Clinical Pharmacokine2cs: Concepts and Prac2ce Applica2ons Ahmed Nader, Ph.D, BCPS Ahmed Awaisu, Ph.D, B.Pharm Upon comple;on of this session, audience are expected to be able
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2011 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /200 pts 1 Question Set I (True or
More informationSelected Clinical Calculations Chapter 10. Heparin-Dosing calculations
Selected Clinical Calculations Chapter 10 Heparin-Dosing calculations Heparin is a heterogeneous group of muco-polysaccharides that have anticoagulant properties (slows clotting time). Heparin salt, as
More informationCareer Corner: Pharmaceutical Calculations for Technicians. Ashlee Mattingly, PharmD, BCPS
Career Corner: Pharmaceutical Calculations for Technicians Ashlee Mattingly, PharmD, BCPS Disclosure I have no actual or potential conflict(s) of interest in relation to this program. Learning Objectives
More informationPHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Final Exam Fall 2010 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers
More informationMultiple IV Bolus Dose Administration
PHARMACOKINETICS Multiple IV Bolus Dose Administration ١ Multiple IV Bolus Dose Administration Objectives: 1) To understand drug accumulation after repeated dose administration 2) To recognize and use
More informationIV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro
IV Vancomycin dosing and Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary Medicine Unique
More informationPrinciples of Pharmacokinetics
Principles of Pharmacokinetics Ákos Csomós MD, PhD Associate Professor Institute of Anaesthesia and Critical Care, Semmelweis University, Budapest, Hungary Pharmacokinetics: Very basics How the organ affects
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationNew drugs necessity for therapeutic drug monitoring
New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range
More informationUSES OF PHARMACOKINETICS
CLINICAL PHARMACOKINETICS Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program Office of Clinical Research Training and Medical Education National Institutes of Health Clinical Center
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationPHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 FINAL EXAM FALL 1997 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question Points 1. /14 pts 2. /10 pts 3. /8 pts 4 /8 pts 5. /12 pts 6. /8 pts
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationMEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol
I. PURPOSE MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol To allow standardized pharmacist management of IV vancomycin in the inpatient setting using evidence-based guidelines
More informationPharmacokinetic parameters: Halflife
Pharmacokinetic parameters: Halflife (t 1/2 ) 1. By definition t 1/2 is the time required for the concentration to fall by one half. For drugs with first order kinetics this is a constant. 2. Half-life
More informationPHENYTOIN DOSING INFORMATION. Adult Dosage
PHENYTOIN DRUGDEX Evaluations DOSING INFORMATION Adult Dosage Normal Dosage Important Note ) Due to the risk of severe hypotension and cardiac arrhythmias, the rate of IV phenytoin administration should
More informationAminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive
Aminoglycosides Uses: Treatment of serious gram-negative systemic infections and some grampositive infections such as infective endocarditis. Disadvantage: aminoglycosides are their association with nephrotoxicity
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationTarget Concentration Intervention
1 Target Concentration Intervention Dose Individualization using Monitoring of Patient Response Nick Holford University of Auckland 2 Objectives 1) Appreciate how a target concentration (TC) strategy is
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1991 December ; 23(6): 2777 2779. Pharmacokinetics of Cyclosporine and Nephrotoxicity in Orthotopic Liver Transplant
More informationPharmacokinetics Overview
Pharmacokinetics Overview Disclaimer: This handout and the associated lectures are intended as a very superficial overview of pharmacokinetics. Summary of Important Terms and Concepts - Absorption, peak
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationAUGMENTED RENAL CLEARANCE and its clinical implications. Professor Jeffrey Lipman
AUGMENTED RENAL CLEARANCE and its clinical implications Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Introduction Recommended dosages
More informationLippincott Questions Pharmacology
Lippincott Questions Pharmacology Edition Two: Chapter One: 1.Which one of the following statements is CORRECT? A. Weak bases are absorbed efficiently across the epithelial cells of the stomach. B. Coadministration
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationOMCJH.CHEM.COLL.INF.1001 Therapeutic Drug Monitoring Guidelines
OMCJH.CHEM.COLL.INF.1001 Copy of version 1.0 (approved and current) Last Approval or Periodic Review Completed 10/5/2017 Next Periodic Review Needed On or Before 10/5/2019 Effective Date 10/5/2017 Controlled
More information(Max 2 g) = to nearest 250 mg
Appendix 1 (part 1 of 8): Rubric for competency assessment of pharmacists prescribing and managing vancomycin Empiric Dosing Phase Pts Yes No Data Error OP Did the pharmacist document the indication 2
More informationANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO
ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept
More information2015 Updates in Therapeutics: The Pharmacotherapy Preparatory Review & Recertification Course Pharmacokinetics: A Refresher Curtis L.
2015 Updates in Therapeutics: The Pharmacotherapy Preparatory Review & Recertification Course Pharmacokinetics: A Refresher Curtis L. Smith, Pharm.D., BCPS Ferris State University Conflict of Interest
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationComparative Study of Different Digoxin Treatment Regimens in Egyptian Hospitals. For Partial Fulfillment of Master Degree in Pharmaceutical Sciences
Comparative Study of Different Digoxin Treatment Regimens in Egyptian Hospitals A Thesis presented by Sahar Atef Azmy Al Shabasy, BSc Teaching Assistant, Clinical Pharmacy Department, Faculty of Pharmacy,
More informationAdult Institutional Pharmacokinetics Protocol
Adult Institutional Pharmacokinetics Protocol Policy Title: Clinical Pharmacokinetics (PK) Service Policy Policy Statement: It is the policy of UMHC that PK consult orders (for vancomycin or aminoglycosides)
More informationVancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy
Vancomycin Pharmacokinetics Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy Goals Review the PK properties of vancomycin Compare and contrast methods of dosage regimen design for vancomycin
More informationBassett Healthcare Clinical Laboratory
Therapeutic Drug Level Collection Guidelines Anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, primidone, valproic acid) Consider collecting after steady state conditions are reached, i.e.
More informationFairview Southdale Hospital Total Points: 50 RN/LPN Medication Assessment Passing: 45
Fairview Southdale Hospital Total Points: 50 RN/LPN Medication Assessment Passing: 45 1. Your diabetic patient is to be started on an insulin drip at 8 units/hour. The insulin is supplied: 100 units in
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationAssessing Renal Function: What you Didn t Know You Didn t Know
Assessing Renal Function: What you Didn t Know You Didn t Know Presented By Tom Wadsworth PharmD, BCPS Associate Clinical Professor UAA/ISU Doctor of Pharmacy Program Idaho State University College of
More informationPharmacotherapy Issues in the Pediatric Population
Pharmacotherapy Issues in the Pediatric Population Continuing Professional Pharmacy Development Dr. Shane Pawluk, PharmD Dr. Andrea Cartwright, PharmD Dr. Maryam Khaja March 26, 2014 Outline Didactic Session
More informationPharmacokinetic Calculations
Pharmacokinetic Calculations Introduction. Pharmacokinetics involves the relationship between concentration of drug (and its metabolites), measured most often in plasma, drug dosage, and time. A vast majority
More informationNonparenteral medications
Nonparenteral medications Capsules and unscored tablets are rounded to the nearest whole tablet. Scored tablets are rounded to the nearest 1/2 tablet. Liquid medications are rounded to one decimal place
More informationPopulation Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development. Leon Aarons Manchester Pharmacy School University of Manchester
Population Pharmacokinetics and Pharmacodynamics as a Tool in Drug Development Leon Aarons Manchester Pharmacy School University of Manchester Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics
More informationValproate Case 3: Formulations Jose de Leon, MD
Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided
More informationPharmacokinetics Applied to the Treatment of Asthma
Pharmacokinetics Applied to the Treatment of Asthma 2016 edition by David C. McMillan, PhD Department of Pharmacology and Experimental Neuroscience College of Medicine University of Nebraska Medical Center
More informationClinical Toxicology Toxicity of Digitalis Glycosides 5 th Year (Lab 3)
Clinical Toxicology Toxicity of Digitalis Glycosides 5 th Year (Lab 3) Lecturer: Rua Abbas Al-Hamdy Department of Pharmacology & Toxicology University of Al-Mustansiriyah 2017-2018 Introduction: Digitalis
More informationMedical Mathematics Handout 1.3 Introduction to Dosage Calculations. by Kevin M. Chevalier
Medical Mathematics Handout 1.3 Introduction to Dosage Calculations by Kevin M. Chevalier Now that we covered the foundation of medical mathematics in the first two handouts, we can apply those concepts
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationPHAR 7632 Chapter 16
PHAR 7632 Chapter 16 Routes of Excretion Routes of Excretion Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe the various routes
More informationNOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions
AC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions FAQ document jointly prepared by NHSGGC Haematology Service & Medicines Infmation On behalf of the Heart MCN
More information1 Acute Lymphoblastic Leukaemia
1 Acute Lymphoblastic Leukaemia 1.05 Intensification - Philadelphia Negative Patients Indication ALL Philadelphia negative patients Pre-treatment Evaluation The intensification module begins two weeks
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationEach tablet contains:
Composition: Each tablet contains: Tolvaptan 15/30mg Pharmacokinetic properties: In healthy subjects the pharmacokinetics of tolvaptan after single doses of up to 480 mg and multiple doses up to 300 mg
More informationPHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 5127 Second Exam Fall 2012 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet TOTAL /150 pts 1 Question Set I (True or
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationOutline. How should we do TDM? Does the evidence support TDM outcomes
Overcoming Barriers to TDM: Information and the TDM Renaissance How to integrate PK intelligence with routine clinical data Alexander A. Vinks, PharmD, PhD, FCP Professor, Director Pediatric Pharmacology
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationPHA Final Exam Fall 2001
PHA 5127 Final Exam Fall 2001 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Question/Points 1. /12 pts 2. /8 pts 3. /12 pts 4. /20 pts 5. /27 pts 6. /15
More informationSLCC Math 1020 Fall 2010 Final Exam Name: Part I: You are not allowed to use calculators, books, or notes. Answer all questions. Do it by yourself.
SLCC Math 1020 Fall 2010 Final Exam Name: Part I: You are not allowed to use calculators, books, or notes. Answer all questions. Do it by yourself. 1. Use the adult s nomogram to find the BSA of a person
More informationChapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University
Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University Estimating renal function An accurate estimation of renal
More informationRHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY
RHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY H Nägele (1)*, S.Behrens (1), S. Hashagen (1), M Azizi (2) 1) St. Adolfstift, Medical Clinic, Reinbek, Germany (Director:
More information